SciGene Moves to Larger Manufacturing and Research Space
News Nov 10, 2006
SciGene has signed a long-term lease on a new manufacturing facility that nearly doubles the size of its current headquarters.
"Our new facility provides much needed room for increased design, assembly, and quality control of our products," says Terry Gill, Director of Product Manufacturing.
The new facility will allow the Company to remain in Sunnyvale while increasing assembly area to build its lines of microarray laboratory equipment; including the BriteSpot™ Microarray Workstation, Little Dipper™ Microarray Processor, and the Hybex® Microarray Incubation System.
The larger building will also be used to expand R&D activities on new products.
"The popularity of our microarray products is growing rapidly, particularly at core laboratories," said Dr. Jim Stanchfield, President and CEO.
"This new facility will allow SciGene to scale up our production, marketing and distribution efforts so that we are well positioned to take advantage of this rapid growth."
Located in Sunnyvale, California in a region referred to as "Biotech Bay", the total size of SciGene’s new building is approximately 7,000 sq. ft., including more than 3,000 sq. ft. of assembly and warehouse space.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.